Department of Neurology, Focus Program Translational Neuroscience and Immunotherapy, Rhine-Main Neuroscience Network, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Eur J Neurol. 2021 Mar;28(3):1086-1089. doi: 10.1111/ene.14692.
Neurological immune-mediated side effects are rare but often severe complications of immune checkpoint inhibitor (ICI) treatment. This report describes a severe case of nivolumab/ipilimumab-associated glutamic acid decarboxylase 65-positive autoimmune encephalitis. It proposes neurofilament light chain levels, a biomarker indicating axonal damage, in the cerebrospinal fluid and serum as a putative novel biomarker for this diagnostically and therapeutically challenging entity with an often unfavorable outcome. Additionally, we provide an overview of previous reports of patients developing autoimmune encephalitis under ICI treatment.
神经免疫介导的副作用较为罕见，但常是免疫检查点抑制剂（ICI）治疗的严重并发症。本报告描述了一例严重的纳武单抗/伊匹单抗相关谷氨酸脱羧酶 65 阳性自身免疫性脑炎。我们提出神经丝轻链水平（一种指示轴索损伤的生物标志物）作为脑脊液和血清中的潜在新型生物标志物，用于诊断和治疗具有经常预后不良的这种具有挑战性的实体。此外，我们还对接受 ICI 治疗后发生自身免疫性脑炎的患者的以往报告进行了概述。
